Abstract
Background
Tumor marker screening may be useful to evaluate tumor response and detect tumor recurrence. However, usefulness and cut-off value of squamous-cell carcinoma antigen (SCC-Ag) for recurrence and survival has not yet established in cervical cancer.
Methods
From January 2010 to October 2016, 304 patients with cervical squamous-cell carcinomas with FIGO stage IB-IVA who underwent curative chemoradiotherapy followed by brachytherapy at four institutions were included in this study. Serum SCC-Ag level was measured before treatment, re-measured after completion of treatment, and again at the time of relapse during follow-up. SCC-Ag levels at each measurement point were analyzed using receiver operating characteristic (ROC) curve. Their associations with recurrence-free survival (RFS) and overall survival (OS) were analyzed.
Results
During a median follow-up time of 36.5 months, there were 66 (21.7%) recurrences and 76 (25.0%) deaths. The ROC curve showed optimal Youden indices were 4, 1.5, and 4 ng/mL at pretreatment, treatment, and recurrence, respectively. In patients with SCC-Ag ≥ 4 ng/mL, not SCC-Ag < 4 ng/mL before treatment, post-treatment SCC-Ag level (≥ 1.5 ng/mL vs. < 1.5 ng/mL) showed significant differences in 3-year RFS (65.5% vs. 45.0%, p < 0.001) and OS (78.5% vs. 55.4%, p < 0.001). In 66 recurrent patients, patients with SCC-Ag ≥ 4 ng/mL at recurrence showed a significantly lower OS rate than others (59.5% vs. 33.0%, p = 0.041).
Conclusions
SCC-Ag level after treatment and at recurrence was useful for predicting recurrence and survival only when its pretreatment value was high (≥ 4 ng/mL).
Similar content being viewed by others
Abbreviations
- FIGO:
-
International Federation Gynecology Obstetrics
- CRT:
-
Chemoradiotherapy
- ICR:
-
Intracavitary radiotherapy
- OS:
-
Overall survival
- RFS:
-
Recurrence-free survival
- ROC:
-
Receiver operating characteristic
- SCC-Ag:
-
Squamous-cell carcinoma antigen
References
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68:394–424
Bodurka-Bevers D, Morris M, Eifel PJ et al (2000) Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78:187–193
Salani R, Backes FJ, Fung Kee Fung M et al (2011) Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 204:466–478
Vistad I, Cvancarova M, Salvesen HB (2012) Follow-up of gynecological cancer patients after treatment—the views of European experts in gynecologic oncology. Acta Obstet Gynecol Scand 91:1286–1292
Kato H, Torigoe T (1977) Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 40:1621–1628
Jeong BK, Choi DH, Huh SJ et al (2011) The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiat Oncol J 29:191–198
Jeong BK, Huh SJ, Choi DH et al (2013) Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer. Cancer Res Treat 45:48–54
Shimura K, Mabuchi S, Yokoi T et al (2013) Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice. J Gynecol Oncol 24:321–329
Choi KH, Lee SW, Yu M et al (2019) Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol 30:e1
Yamanoi K, Matsumura N, Kido A et al (2013) A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography. Gynecol Oncol 131:701–707
Lehtovirta P, Viinikka L, Ylikorkala O (1990) Comparison between squamous cell carcinoma-associated antigen and CA-125 in patients with carcinoma of the cervix. Gynecol Oncol 37:276–278
Scambia G, Panici PB, Baiocchi G et al (1991) The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol 164:631–636
Salvatici M, Achilarre MT, Sandri MT et al (2016) Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: role in the early diagnosis of recurrence. Gynecol Oncol 142:115–119
Charakorn C, Thadanipon K, Chaijindaratana S et al (2018) The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: a systematic review and meta-analysis. Gynecol Oncol 150:190–200
Hong JH, Tsai CS, Chang JT et al (1998) The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 41:823–830
Oh J, Bae JY (2018) Optimal cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance. Obstet Gynecol Sci 61:337–343
Kubik S, Moszynska-Zielinska M, Fijuth J et al (2019) Assessment of the relationship between serum squamous cell carcinoma antigen (SCC-Ag) concentration in patients with locally advanced squamous cell carcinoma of the uterine cervix and the risk of relapse. Prz Menopauzalny 18:23–26
Wang Y, Cui T, Du L et al (2017) The correlation between the serum squamous carcinoma antigen and the prognosis of recurrent cervical squamous carcinoma. J Clin Lab Anal 20:31
Yoon SM, Shin KH, Kim J-Y et al (2010) Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy. Radiat Oncol 5:78
Acknowledgements
Statistical analyses performed in this article were advised by Catholic Medical Center Clinical Research Coordinating Center.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Choi, K.H., Yu, M., Jeong, S. et al. Can serial evaluation of serum SCC-Ag-level predict tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix treated with definitive chemoradiotherapy? A multi-institutional analysis. Int J Clin Oncol 25, 1405–1411 (2020). https://doi.org/10.1007/s10147-020-01664-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-020-01664-3